Trade this ETF at your broker
Index | Harbor Health Care |
Investment focus | Equity, World, Health Care |
Fund size | EUR 15 m |
Total expense ratio | 0.89% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 17.82% |
Inception/ Listing Date | 4 April 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | HANetf |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | J.P. Morgan Administration Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | J.P. Morgan SE - Dublin Branch |
Revision Company | Ernst and Young |
Fiscal Year End | 31 March |
Swiss representative | Waystone |
Swiss paying agent | Helvetische Bank |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Ascendis Pharma | 9.74% |
AbbVie, Inc. | 7.68% |
Legend Biotech | 7.56% |
Pfizer Inc. | 6.36% |
Masimo Corp. | 5.56% |
Option Care Health | 4.52% |
ICON plc | 4.28% |
UnitedHealth Group | 3.81% |
Lantheus Holdings, Inc. | 3.57% |
Vaxcyte | 3.47% |
United States | 72.73% |
Ireland | 4.30% |
Switzerland | 1.03% |
Other | 21.94% |
Health Care | 77.81% |
Financials | 0.93% |
Other | 21.26% |
Broker | Rating | Execution fee | Account fee | |
---|---|---|---|---|
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
1.50€ 1.50% | 0.00€ | View offer* | ||
1.50€ 1.50% | 0.00€ | View offer* |
Broker | Rating | Order fee | ETF savings plans | |
---|---|---|---|---|
0.99€ | 2593 | View offer* | ||
1.00€ | 2414 | View offer* | ||
0.00€ | 1624 | View offer* | ||
0.00€ | 1087 | View offer* | ||
0.00€ | 897 | View offer* |
YTD | -3.32% |
1 month | -6.42% |
3 months | -1.99% |
6 months | -2.29% |
1 year | +6.48% |
3 years | -33.16% |
5 years | -14.99% |
Since inception (MAX) | -7.50% |
2023 | -1.92% |
2022 | -25.63% |
2021 | +1.00% |
2020 | +17.19% |
Volatility 1 year | 17.82% |
Volatility 3 years | 23.94% |
Volatility 5 years | 24.13% |
Return per risk 1 year | 0.36 |
Return per risk 3 years | -0.52 |
Return per risk 5 years | -0.13 |
Maximum drawdown 1 year | -11.92% |
Maximum drawdown 3 years | -42.54% |
Maximum drawdown 5 years | -45.82% |
Maximum drawdown since inception | -45.82% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | W311 | - - | - - | - |
Borsa Italiana | EUR | WELL | WELL IM WELLEUIV | WELL.MI WELLEURINAV=SOLA | RBC Europe Ltd |
Euronext Paris | EUR | WELL | WELL FP WELLEUIV | WELP.PA WELLEURINAV=SOLA | RBC Europe Ltd |
London Stock Exchange | GBX | WELP | RBC Europe Ltd | ||
London Stock Exchange | USD | WELL | WELL LN | HAWELL.L | RBC Europe Ltd |
London Stock Exchange | GBP | - | WELP LN | WELP.L | RBC Europe Ltd |
SIX Swiss Exchange | CHF | WELL | WELL SW WELLEUIV | WELL.S WELLEURINAV=SOLA | RBC Europe Ltd |
XETRA | EUR | W311 | W311 GY WELLEUIV | W311.DE WELLEURINAV=SOLA | RBC Europe Ltd |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 989 | 0.40% p.a. | Accumulating | Sampling |
L&G Healthcare Breakthrough UCITS ETF USD Acc | 60 | 0.49% p.a. | Accumulating | Full replication |
L&G Pharma Breakthrough UCITS ETF | 15 | 0.49% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |